Celltrion Obtains Canadian Approval To Sell Bevacizumab Biosimilar

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Explore Firm Details

United States Food, Drugs, Healthcare, Life Sciences

Beth Ashbridge, Ph.D.

Article Insights

Beth Ashbridge, Ph.D.’s articles from Goodwin Procter LLP are most popular:

with readers working within the Pharmaceuticals & BioTech industries

Goodwin Procter LLP are most popular:

within Transport and Strategy topic(s)

This week, Celltrion obtained full label approval from Health Canada to sell Vegzelma (CT-P16), a bevacizumab biosimilar indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and glioblastoma. Celltrion has secured sales licenses for Vegzelma in 35 countries, including Korea, Europe, U.K., and Japan.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Authors

Celltrion Obtains Canadian Approval To Sell Bevacizumab Biosimilar

Contributor

Food, Drugs, Healthcare, Life Sciences

Contributor

United States